Department of Cardiovascular and Thoracic Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris-Sorbonne University, Paris, France.
Department of Cardiovascular and Thoracic Surgery, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris-Sorbonne University, Paris, France.
J Am Coll Cardiol. 2023 Mar 7;81(9):897-909. doi: 10.1016/j.jacc.2022.12.018.
Outcomes of patients requiring venoarterial extracorporeal membrane oxygenation (VA-ECMO) vary greatly by etiology, but large studies that incorporate the spectrum of shock supported with ECMO are rare.
The purpose of this study was to describe the etiology-related outcome of patients with shock supported with peripheral VA-ECMO.
All consecutive adults with peripheral VA-ECMO between January 2015 and August 2018 at Pitié-Salpêtrière Hospital (Paris, France) were included in this retrospective observational study. The indication for VA-ECMO was cardiogenic shock. Rates of hospital death and neurological, renal, and pulmonary complications were evaluated according to etiology.
Among 1,253 patients, hospital and 5-year survival rates were, respectively, 73.3% and 57.3% for primary graft failure, 58.6% and 54.0% for drug overdose, 53.2% and 45.3% for dilated cardiomyopathy, 51.6% and 50.0% for arrhythmic storm, 46.8% and 38.3% for massive pulmonary embolism, 44.4% and 42.4% for sepsis-induced cardiogenic shock, 37.9% and 32.9% for fulminant myocarditis, 37.3% and 31.5% for acute myocardial infarction, 34.6% and 33.3% for postcardiotomy excluding primary graft failure, 25.7% and 22.8% for other/unknown etiology, and 11.1% and 0.0% for refractory vasoplegia shock. Renal failure requiring hemodialysis developed in 50.0%, neurological complications in 16.0%, and hydrostatic pulmonary edema in 9.0%.
Although the outcome differs depending on etiology, this difference is related more to the severity of the situation associated with the cause rather than the cause of the shock per se. Survival to 5 years varied by cause, which may reflect the natural course of the chronic disease and illustrates the need for long-term follow-up.
接受静脉-动脉体外膜肺氧合(VA-ECMO)治疗的患者的结局因病因而异,但很少有研究包含接受 ECMO 支持的休克患者的全貌。
本研究旨在描述接受外周 VA-ECMO 支持的休克患者的病因相关结局。
这项回顾性观察研究纳入了 2015 年 1 月至 2018 年 8 月期间在巴黎皮提耶-萨尔佩特里埃医院接受外周 VA-ECMO 的所有连续成年患者。VA-ECMO 的适应证为心原性休克。根据病因评估医院死亡和神经、肾和肺部并发症的发生率。
在 1253 例患者中,原发性移植物功能衰竭、药物过量、扩张型心肌病、心律失常风暴、大面积肺栓塞、脓毒症性心原性休克、暴发性心肌炎、急性心肌梗死、心脏手术后排除原发性移植物功能衰竭、其他/未知病因、难治性血管扩张性休克的医院和 5 年生存率分别为 73.3%和 57.3%、58.6%和 54.0%、53.2%和 45.3%、51.6%和 50.0%、46.8%和 38.3%、44.4%和 42.4%、37.9%和 32.9%、37.3%和 31.5%、34.6%和 33.3%、25.7%和 22.8%、11.1%和 0.0%。需要血液透析的肾衰竭发生率为 50.0%、神经系统并发症发生率为 16.0%、静水压性肺水肿发生率为 9.0%。
尽管结局因病因而异,但这种差异更多地与导致休克的病因相关的严重程度有关,而不是与休克本身的病因有关。5 年生存率因病因而异,这可能反映了慢性疾病的自然病程,并说明了需要长期随访。